According to the current therapeutic guidelines, early-stage HR-positive breast cancer patients should receive hormone therapy (aromatase inhibitors or tamoxifen) for approximately 5–10 years [22,23]. This evidence concerns the gene CYP19A1 and breast carcinoma.